was read the article
array:25 [ "pii" => "S0021755716302431" "issn" => "00217557" "doi" => "10.1016/j.jped.2017.06.004" "estado" => "S300" "fechaPublicacion" => "2018-01-01" "aid" => "523" "copyright" => "Sociedade Brasileira de Pediatria" "copyrightAnyo" => "2017" "documento" => "article" "crossmark" => 1 "licencia" => "http://creativecommons.org/licenses/by-nc-nd/4.0/" "subdocumento" => "fla" "cita" => "J Pediatr (Rio J). 2018;94:62-8" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:2 [ "total" => 1409 "formatos" => array:3 [ "EPUB" => 141 "HTML" => 981 "PDF" => 287 ] ] "Traduccion" => array:1 [ "pt" => array:20 [ "pii" => "S2255553617300915" "issn" => "22555536" "doi" => "10.1016/j.jpedp.2017.08.009" "estado" => "S300" "fechaPublicacion" => "2018-01-01" "aid" => "523" "copyright" => "Sociedade Brasileira de Pediatria" "documento" => "article" "crossmark" => 1 "licencia" => "http://creativecommons.org/licenses/by-nc-nd/4.0/" "subdocumento" => "fla" "cita" => "J Pediatr (Rio J). 2018;94:62-8" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:2 [ "total" => 2723 "formatos" => array:3 [ "EPUB" => 110 "HTML" => 2125 "PDF" => 488 ] ] "pt" => array:13 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">Artigo Original</span>" "titulo" => "Bromopride, metoclopramide, or ondansetron for the treatment of vomiting in the pediatric emergency department: a randomized controlled trial" "tienePdf" => "pt" "tieneTextoCompleto" => "pt" "tieneResumen" => array:2 [ 0 => "en" 1 => "pt" ] "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "62" "paginaFinal" => "68" ] ] "titulosAlternativos" => array:1 [ "pt" => array:1 [ "titulo" => "Bromoprida, metoclopramida ou ondansetrona no tratamento de vômito no departamento de emergência pediátrica: ensaio controlado randomizado" ] ] "contieneResumen" => array:2 [ "en" => true "pt" => true ] "contieneTextoCompleto" => array:1 [ "pt" => true ] "contienePdf" => array:1 [ "pt" => true ] "resumenGrafico" => array:2 [ "original" => 0 "multimedia" => array:7 [ "identificador" => "fig0005" "etiqueta" => "Figura 1" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr1.jpeg" "Alto" => 2051 "Ancho" => 2237 "Tamanyo" => 272919 ] ] "descripcion" => array:1 [ "pt" => "<p id="spar0055" class="elsevierStyleSimplePara elsevierViewall">Fluxograma de participação, tratamento e acompanhamento Consort.</p>" ] ] ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "Matias Epifanio, Janete de L. Portela, Jefferson P. Piva, Cristina H. Targa Ferreira, Edgar E. Sarria, Rita Mattiello" "autores" => array:6 [ 0 => array:2 [ "nombre" => "Matias" "apellidos" => "Epifanio" ] 1 => array:2 [ "nombre" => "Janete de L." "apellidos" => "Portela" ] 2 => array:2 [ "nombre" => "Jefferson P." "apellidos" => "Piva" ] 3 => array:2 [ "nombre" => "Cristina H. Targa" "apellidos" => "Ferreira" ] 4 => array:2 [ "nombre" => "Edgar E." "apellidos" => "Sarria" ] 5 => array:2 [ "nombre" => "Rita" "apellidos" => "Mattiello" ] ] ] ] ] "idiomaDefecto" => "pt" "Traduccion" => array:1 [ "en" => array:9 [ "pii" => "S0021755716302431" "doi" => "10.1016/j.jped.2017.06.004" "estado" => "S300" "subdocumento" => "" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:1 [ "total" => 0 ] "idiomaDefecto" => "en" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0021755716302431?idApp=UINPBA000049" ] ] "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2255553617300915?idApp=UINPBA000049" "url" => "/22555536/0000009400000001/v2_202010270619/S2255553617300915/v2_202010270619/pt/main.assets" ] ] "itemSiguiente" => array:20 [ "pii" => "S0021755716303758" "issn" => "00217557" "doi" => "10.1016/j.jped.2017.03.010" "estado" => "S300" "fechaPublicacion" => "2018-01-01" "aid" => "533" "copyright" => "Sociedade Brasileira de Pediatria" "documento" => "article" "crossmark" => 1 "licencia" => "http://creativecommons.org/licenses/by-nc-nd/4.0/" "subdocumento" => "fla" "cita" => "J Pediatr (Rio J). 2018;94:69-75" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:2 [ "total" => 711 "formatos" => array:3 [ "EPUB" => 80 "HTML" => 360 "PDF" => 271 ] ] "en" => array:12 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">Original article</span>" "titulo" => "Advanced bone age as an indicator facilitates the diagnosis of precocious puberty" "tienePdf" => "en" "tieneTextoCompleto" => "en" "tieneResumen" => array:2 [ 0 => "en" 1 => "pt" ] "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "69" "paginaFinal" => "75" ] ] "titulosAlternativos" => array:1 [ "pt" => array:1 [ "titulo" => "Idade óssea avançada como um indicador de facilitação do diagnóstico de puberdade precoce" ] ] "contieneResumen" => array:2 [ "en" => true "pt" => true ] "contieneTextoCompleto" => array:1 [ "en" => true ] "contienePdf" => array:1 [ "en" => true ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "Yue-Qin Xu, Gui-Mei Li, Yan Li" "autores" => array:3 [ 0 => array:2 [ "nombre" => "Yue-Qin" "apellidos" => "Xu" ] 1 => array:2 [ "nombre" => "Gui-Mei" "apellidos" => "Li" ] 2 => array:2 [ "nombre" => "Yan" "apellidos" => "Li" ] ] ] ] ] "idiomaDefecto" => "en" "Traduccion" => array:1 [ "pt" => array:9 [ "pii" => "S2255553617301088" "doi" => "10.1016/j.jpedp.2017.08.020" "estado" => "S300" "subdocumento" => "" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:1 [ "total" => 0 ] "idiomaDefecto" => "pt" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2255553617301088?idApp=UINPBA000049" ] ] "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0021755716303758?idApp=UINPBA000049" "url" => "/00217557/0000009400000001/v2_202010230715/S0021755716303758/v2_202010230715/en/main.assets" ] "itemAnterior" => array:20 [ "pii" => "S0021755716303084" "issn" => "00217557" "doi" => "10.1016/j.jped.2017.04.004" "estado" => "S300" "fechaPublicacion" => "2018-01-01" "aid" => "498" "copyright" => "Sociedade Brasileira de Pediatria" "documento" => "article" "crossmark" => 1 "licencia" => "http://creativecommons.org/licenses/by-nc-nd/4.0/" "subdocumento" => "fla" "cita" => "J Pediatr (Rio J). 2018;94:56-61" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:2 [ "total" => 958 "formatos" => array:3 [ "EPUB" => 110 "HTML" => 546 "PDF" => 302 ] ] "en" => array:11 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">Original article</span>" "titulo" => "Heliox delivered by high flow nasal cannula improves oxygenation in infants with respiratory syncytial virus acute bronchiolitis" "tienePdf" => "en" "tieneTextoCompleto" => "en" "tieneResumen" => array:2 [ 0 => "en" 1 => "pt" ] "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "56" "paginaFinal" => "61" ] ] "contieneResumen" => array:2 [ "en" => true "pt" => true ] "contieneTextoCompleto" => array:1 [ "en" => true ] "contienePdf" => array:1 [ "en" => true ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "Wael Seliem, Amira M. Sultan" "autores" => array:2 [ 0 => array:2 [ "nombre" => "Wael" "apellidos" => "Seliem" ] 1 => array:2 [ "nombre" => "Amira M." "apellidos" => "Sultan" ] ] ] ] ] "idiomaDefecto" => "en" "Traduccion" => array:1 [ "pt" => array:9 [ "pii" => "S2255553617300575" "doi" => "10.1016/j.jpedp.2017.05.001" "estado" => "S300" "subdocumento" => "" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:1 [ "total" => 0 ] "idiomaDefecto" => "pt" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S2255553617300575?idApp=UINPBA000049" ] ] "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0021755716303084?idApp=UINPBA000049" "url" => "/00217557/0000009400000001/v2_202010230715/S0021755716303084/v2_202010230715/en/main.assets" ] "en" => array:20 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">Original article</span>" "titulo" => "Bromopride, metoclopramide, or ondansetron for the treatment of vomiting in the pediatric emergency department: a randomized controlled trial" "tieneTextoCompleto" => true "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "62" "paginaFinal" => "68" ] ] "autores" => array:1 [ 0 => array:4 [ "autoresLista" => "Matias Epifanio, Janete de L. Portela, Jefferson P. Piva, Cristina H. Targa Ferreira, Edgar E. Sarria, Rita Mattiello" "autores" => array:6 [ 0 => array:4 [ "nombre" => "Matias" "apellidos" => "Epifanio" "email" => array:1 [ 0 => "mepifanio@hotmail.com" ] "referencia" => array:3 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">a</span>" "identificador" => "aff0005" ] 1 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">b</span>" "identificador" => "aff0010" ] 2 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">*</span>" "identificador" => "cor0005" ] ] ] 1 => array:3 [ "nombre" => "Janete de L." "apellidos" => "Portela" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">c</span>" "identificador" => "aff0015" ] ] ] 2 => array:3 [ "nombre" => "Jefferson P." "apellidos" => "Piva" "referencia" => array:2 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">d</span>" "identificador" => "aff0020" ] 1 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">e</span>" "identificador" => "aff0025" ] ] ] 3 => array:3 [ "nombre" => "Cristina H. Targa" "apellidos" => "Ferreira" "referencia" => array:2 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">f</span>" "identificador" => "aff0030" ] 1 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">g</span>" "identificador" => "aff0035" ] ] ] 4 => array:3 [ "nombre" => "Edgar E." "apellidos" => "Sarria" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">h</span>" "identificador" => "aff0040" ] ] ] 5 => array:3 [ "nombre" => "Rita" "apellidos" => "Mattiello" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">a</span>" "identificador" => "aff0005" ] ] ] ] "afiliaciones" => array:8 [ 0 => array:3 [ "entidad" => "Pontifícia Universidade Católica do Rio Grande do Sul (PUCRS), School of Medicine, Porto Alegre, RS, Brazil" "etiqueta" => "a" "identificador" => "aff0005" ] 1 => array:3 [ "entidad" => "Pontifícia Universidade Católica do Rio Grande do Sul (PUCRS), Hospital São Lucas, Departamento de Gastroenterologia Pediátrica, Porto Alegre, RS, Brazil" "etiqueta" => "b" "identificador" => "aff0010" ] 2 => array:3 [ "entidad" => "Universidade Federal de Santa Maria (UFSM), Hospital Universitário de Santa Maria, Santa Maria, RS, Brazil" "etiqueta" => "c" "identificador" => "aff0015" ] 3 => array:3 [ "entidad" => "Universidade Federal do Rio Grande do Sul (UFRGS), School of Medicine, Porto Alegre, RS, Brazil" "etiqueta" => "d" "identificador" => "aff0020" ] 4 => array:3 [ "entidad" => "Hospital de Clínicas de Porto Alegre (HCPA), Departamento de Emergência Pediátrica e Cuidados Intensivos Pediátricos, Porto Alegre, RS, Brazil" "etiqueta" => "e" "identificador" => "aff0025" ] 5 => array:3 [ "entidad" => "Universidade Federal de Ciências da Saúde de Porto Alegre (UFCSPA), Porto Alegre, RS, Brazil" "etiqueta" => "f" "identificador" => "aff0030" ] 6 => array:3 [ "entidad" => "Hospital da Criança Santo Antônio (HCSA), Departamento de Gastroenterologia Pediátrica, Porto Alegre, RS, Brazil" "etiqueta" => "g" "identificador" => "aff0035" ] 7 => array:3 [ "entidad" => "Universidade de Santa Cruz (UNISC), School of Medicine, Departamento de Biologia e Farmácia, Santa Cruz do Sul, RS, Brazil" "etiqueta" => "h" "identificador" => "aff0040" ] ] "correspondencia" => array:1 [ 0 => array:3 [ "identificador" => "cor0005" "etiqueta" => "⁎" "correspondencia" => "Corresponding author." ] ] ] ] "titulosAlternativos" => array:1 [ "pt" => array:1 [ "titulo" => "Bromoprida, metoclopramida ou ondansetrona no tratamento de vômito no departamento de emergência pediátrica: ensaio controlado randomizado" ] ] "resumenGrafico" => array:2 [ "original" => 0 "multimedia" => array:7 [ "identificador" => "fig0005" "etiqueta" => "Figure 1" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr1.jpeg" "Alto" => 2050 "Ancho" => 2236 "Tamanyo" => 235285 ] ] "descripcion" => array:1 [ "en" => "<p id="spar0055" class="elsevierStyleSimplePara elsevierViewall">CONSORT flowchart of enrollment, treatment, and follow-up.</p>" ] ] ] "textoCompleto" => "<span class="elsevierStyleSections"><span id="sec0005" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0065">Introduction</span><p id="par0005" class="elsevierStylePara elsevierViewall">Acute gastroenteritis (AGE) is one of the most common causes of morbidity and mortality in children, contributing to numerous emergency department visits and pediatric hospitalizations. AGE is considered an important public health issue; according to the World Health Organization (WHO) and the United Nations Children's Fund (UNICEF), there are about two billion cases of diarrheal disease worldwide every year, and 1.9 million children younger than 5 years of age perish from diarrhea each year, mostly in developing countries.<a class="elsevierStyleCrossRef" href="#bib0090"><span class="elsevierStyleSup">1</span></a> Generally, AGE is an acute and self-limiting disease, which usually lasts 3–7 days.<a class="elsevierStyleCrossRef" href="#bib0095"><span class="elsevierStyleSup">2</span></a></p><p id="par0010" class="elsevierStylePara elsevierViewall">Vomiting is a common manifestation of AGE that causes discomfort; left untreated, it may lead to dehydration.<a class="elsevierStyleCrossRefs" href="#bib0090"><span class="elsevierStyleSup">1,2</span></a> Oral rehydration therapy (ORT) is the most suitable treatment for children with AGE, but it is challenging in the presence of persistent/refractory emesis.<a class="elsevierStyleCrossRef" href="#bib0095"><span class="elsevierStyleSup">2</span></a> Guidelines state that ORT in children has a high chance of failure in the setting of persistent vomiting, and support the use of intravenous (IV) rehydration in this context.<a class="elsevierStyleCrossRefs" href="#bib0100"><span class="elsevierStyleSup">3,4</span></a> However a recent publication showed that ORT is efficacious even in children with vomiting in a high percentage of cases.<a class="elsevierStyleCrossRefs" href="#bib0100"><span class="elsevierStyleSup">3,4</span></a></p><p id="par0015" class="elsevierStylePara elsevierViewall">When pharmacological intervention is used for persistent nausea and vomiting, it can prevent severe complications due to dehydration.<a class="elsevierStyleCrossRefs" href="#bib0095"><span class="elsevierStyleSup">2,5</span></a> Bromopride, metoclopramide, and ondansetron have been used in clinical practice in these situations.<a class="elsevierStyleCrossRefs" href="#bib0115"><span class="elsevierStyleSup">6,7</span></a></p><p id="par0020" class="elsevierStylePara elsevierViewall">Bromopride has been used since the 1970s; its use has been fully incorporated by pediatricians since then. The recommendation of bromopride remains a reference as a therapeutic resource for various diseases in gastroenterology textbooks and published reviews on prokinetics.<a class="elsevierStyleCrossRef" href="#bib0125"><span class="elsevierStyleSup">8</span></a></p><p id="par0025" class="elsevierStylePara elsevierViewall">Metoclopramide is an anti-emetic widely used in the treatment of vomiting in children, with good results. A study comparing the therapeutic effectiveness of intravenous metoclopramide (72%) and ondansetron (81%) showed that both are effective in stopping vomiting.<a class="elsevierStyleCrossRef" href="#bib0130"><span class="elsevierStyleSup">9</span></a> Some studies found that metoclopramide was associated with adverse effects, such as sedation, agitation, or extrapyramidal reaction.<a class="elsevierStyleCrossRefs" href="#bib0095"><span class="elsevierStyleSup">2,5,8,10</span></a> However, such adverse effects could be secondary to the dosing used; this remains to be clarified.</p><p id="par0030" class="elsevierStylePara elsevierViewall">Ondansetron has been widely used as an anti-emetic in cases of vomiting associated with chemotherapy, radiotherapy, and surgical interventions. Recent studies have shown that the prescription of ondansetron is rising in pediatric emergency departments for treating AGE-associated vomiting.<a class="elsevierStyleCrossRefs" href="#bib0100"><span class="elsevierStyleSup">3,7,11,12</span></a> It has been shown in a recent meta-analysis that ondansetron compared with placebo increased the chance for vomiting cessation up to one hour after drug administration, but there was no difference between the groups after four, 24, and 48<span class="elsevierStyleHsp" style=""></span>h. Treatment with ondansetron compared with placebo reduced the risk of failure of oral rehydration therapy and reduced the risk of hospitalization.<a class="elsevierStyleCrossRef" href="#bib0105"><span class="elsevierStyleSup">4</span></a> A study conducted in the United States and Canada with ondansetron found that 86% of physicians recommended its use, considering its effectiveness effective in improving ORT success and its reasonable cost.<a class="elsevierStyleCrossRef" href="#bib0150"><span class="elsevierStyleSup">13</span></a></p><p id="par0035" class="elsevierStylePara elsevierViewall">Still, more evidence is needed concerning the safety and efficacy of antiemetic use for vomiting in children. The aim of this study was to assess the effectiveness of a single intramuscular dose of bromopride, metoclopramide, and ondansetron to treat acute onset vomiting in a pediatric emergency department.</p></span><span id="sec0010" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0070">Methods</span><span id="sec0015" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0075">Trial design</span><p id="par0040" class="elsevierStylePara elsevierViewall">Controlled clinical trial phase IV, randomized in three parallel groups, to assess the therapeutic effectiveness of ondansetron, bromopride, and metoclopramide in treating vomiting. Patients were randomized in sequential blocks as they became eligible to participate in the study, and similar distribution in each treatment group was ensured. The assignment was made as 1:1:1 for each medication in blocks of fifteen children, including five from each group. The sequential block randomization was not predictable by treating clinicians.</p></span><span id="sec0020" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0080">Changes in trial design</span><p id="par0045" class="elsevierStylePara elsevierViewall">There were no changes in the study design throughout its duration.</p></span><span id="sec0025" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0085">Study setting</span><p id="par0050" class="elsevierStylePara elsevierViewall">The study was conducted in the Pediatric Emergency Department (PedER) of Hospital Universitário de Santa Maria (HUSM), in southern Brazil, between August 2013 and June 2014.</p></span><span id="sec0030" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0090">Eligibility criteria for participants</span><p id="par0055" class="elsevierStylePara elsevierViewall">Inclusion criteria were as follows: children 1–12 years of age, admitted to the PedER with two or more episodes of vomiting in the previous 24<span class="elsevierStyleHsp" style=""></span>h, and considered to need intramuscular anti-emetic medication by the attending physician. The study did not consider the severity or details of the vomiting, but only the attending physician's decision to use anti-emetic medication.</p><p id="par0060" class="elsevierStylePara elsevierViewall">Exclusion criteria were as follows: (a) use of anti-emetic medications in the previous 24<span class="elsevierStyleHsp" style=""></span>h; (b) children with known allergy to bromopride, metoclopramide, and/or ondansetron; (c) severe dehydration, vomiting due to sedation, anesthesia, or chemotherapy; (d) pregnant and/or breast-feeding teenagers; (e) children with heart disease, advanced renal disease, urinary tract infection, epilepsy, intestinal obstruction, appendicitis, meningitis, diabetes mellitus, malnutrition, pneumonia, or brain tumor.</p></span><span id="sec0035" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0095">Interventions</span><p id="par0065" class="elsevierStylePara elsevierViewall">Once subjects were identified as meeting eligibility criteria, they were approached for recruitment. Immediately following recruitment, patients were randomized to a treatment group. The three treatment groups were: group A, bromopride (0.15<span class="elsevierStyleHsp" style=""></span>mg/kg, maximum 10<span class="elsevierStyleHsp" style=""></span>mg); group B, metoclopramide (0.15<span class="elsevierStyleHsp" style=""></span>mg/kg, maximum 10<span class="elsevierStyleHsp" style=""></span>mg); group C, ondansetron, (0.15<span class="elsevierStyleHsp" style=""></span>mg/kg, maximum 8<span class="elsevierStyleHsp" style=""></span>mg). They were all administered as a single intramuscular dose.</p><p id="par0070" class="elsevierStylePara elsevierViewall">Children remained under observation in the PedER until discharged by the attending physician. At the time of discharge, a survey was given to parents or legal guardians to ascertain details on the evolution of symptoms in the 24<span class="elsevierStyleHsp" style=""></span>h following the treatment. Children whose vomiting did not improve 60<span class="elsevierStyleHsp" style=""></span>min following the intervention were prescribed other medications by the attending physician, as they deemed appropriate (typically either intravenous fluid or other anti-emetics).</p><p id="par0075" class="elsevierStylePara elsevierViewall">All assessments within the 24<span class="elsevierStyleHsp" style=""></span>h period of data collection (<span class="elsevierStyleItalic">i.e.</span>, response to treatment at one, six, and 24<span class="elsevierStyleHsp" style=""></span>h post treatment) were made by members of the research team, who were blinded to the intervention. Following discharge, information was collected by phone calls to the caregivers by members of the research team.</p></span><span id="sec0040" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0100">Outcomes</span><p id="par0080" class="elsevierStylePara elsevierViewall">Variables were assessed for the three drugs, at 60<span class="elsevierStyleHsp" style=""></span>min, six hours, and 24<span class="elsevierStyleHsp" style=""></span>h after intervention with IM medication. At 60<span class="elsevierStyleHsp" style=""></span>min, data was obtained regarding the number of children in whom vomiting ceased, acceptance of oral fluids and amount (mL), need for intravenous rehydration, and side effects. After receiving the medication, children were restrained from receiving any oral fluid for 30<span class="elsevierStyleHsp" style=""></span>min; then, children were allowed to drink 300<span class="elsevierStyleHsp" style=""></span>mL of either oral rehydration solution or tap water, given in small amounts using a 10<span class="elsevierStyleHsp" style=""></span>mL syringe by their accompanying parents, to avoid stimulating the emetic reflex as much as possible. The amount of fluids taken orally was measured one hour after initiating its administration. After full oral fluid intake was tolerated, light solid food intake was advised at discharge from the PedER.</p><p id="par0085" class="elsevierStylePara elsevierViewall">Six hours post anti-emetic medication, the number of children that ceased vomiting was recorded, as well as whether they had been discharged home or remained in the PedER. Side effects were also recorded, such as diarrhea, somnolence, or others. Information collected 24<span class="elsevierStyleHsp" style=""></span>h post anti-emetic medication included the number or children that ceased vomiting, returns to PedER due to vomiting or side effects, and side effects at any point in time – like diarrhea, somnolence, or others.</p><p id="par0090" class="elsevierStylePara elsevierViewall">The sample size was calculated based on previous studies, considering the vomit cessation rate at 24<span class="elsevierStyleHsp" style=""></span>h,<a class="elsevierStyleCrossRef" href="#bib0155"><span class="elsevierStyleSup">14</span></a> using the expected values for each medication under study: 60% (ondansetron), 45% (bromopride), and 30% (metoclopramide). The estimated sample was 48 subjects per group (144 children). Estimating attrition of 20%, the final sample size was set at 180 patients.</p><p id="par0095" class="elsevierStylePara elsevierViewall">Continuous variables were expressed as means and standard deviation (SD) or medians with interquartile ranges, depending on their distribution. Similarly, Student's <span class="elsevierStyleItalic">t</span>-test or the Kruskal–Wallis test was used when appropriate. The categorical variables were expressed by percentage and compared by Pearson's chi-squared test or Fisher's exact test. Data was analyzed using SPSS software (IBM Corp. Released 2011. IBM SPSS Statistics for Windows, Version 20.0. NY, USA).</p><p id="par0100" class="elsevierStylePara elsevierViewall">The study was approved by the institutional Review Board (CAAE: 12188513.9.0000.5336), and all parents or legal guardians agreed to participate by signing an informed consent. Clinical Trial registration number: RBR-5ky3ks.</p></span></span><span id="sec0045" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0105">Results</span><span id="sec0050" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0110">Participant flow</span><p id="par0105" class="elsevierStylePara elsevierViewall">One hundred and eighty children were selected and randomized to receive treatment for vomiting in the PedER (<a class="elsevierStyleCrossRef" href="#fig0005">Fig. 1</a>).</p><elsevierMultimedia ident="fig0005"></elsevierMultimedia></span><span id="sec0055" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0115">Losses and exclusions</span><p id="par0110" class="elsevierStylePara elsevierViewall">Five children were excluded (four from the bromopride group and one from the ondansetron group) due to the prescription of a different antiemetic drug by the attending physician.</p></span><span id="sec0060" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0120">Baseline data</span><p id="par0115" class="elsevierStylePara elsevierViewall">No significant differences were observed between study groups in terms of sex, age, weight, and number of episodes of vomiting before administering the study drug (<a class="elsevierStyleCrossRef" href="#tbl0005">Table 1</a>).</p><elsevierMultimedia ident="tbl0005"></elsevierMultimedia></span><span id="sec0065" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0125">Numbers analyzed</span><p id="par0120" class="elsevierStylePara elsevierViewall">175 children completed the study, distributed as follows: group A (bromopride), 59; group B (metoclopramide), 58, and group C (ondansetron), 58. There were no losses in the follow up.</p></span><span id="sec0070" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0130">Outcomes</span><p id="par0125" class="elsevierStylePara elsevierViewall">Of all study participants, only five children (2.9%) vomited in the first hour after receiving medication. Two (3.4%) belonged to group A, and three (5.2%) to group B, with no significant difference between groups (<a class="elsevierStyleCrossRef" href="#tbl0010">Table 2</a>).</p><elsevierMultimedia ident="tbl0010"></elsevierMultimedia><p id="par0130" class="elsevierStylePara elsevierViewall">At 24<span class="elsevierStyleHsp" style=""></span>h, the anti-emetic effect, in terms of number of children having stopped vomiting, was statistically superior in group C compared to groups A and B (96.6% <span class="elsevierStyleItalic">vs</span>. 67.8% and 67.2%, respectively [<span class="elsevierStyleItalic">p</span><span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>0.001]) (<a class="elsevierStyleCrossRef" href="#tbl0010">Table 2</a>).</p><p id="par0135" class="elsevierStylePara elsevierViewall">Oral fluid intake (<a class="elsevierStyleCrossRef" href="#tbl0015">Table 3</a>), evaluated 30<span class="elsevierStyleHsp" style=""></span>min after receiving medication, was statistically better (<span class="elsevierStyleItalic">p</span><span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>0.050) for group C (200<span class="elsevierStyleHsp" style=""></span>mL), compared to groups A (150<span class="elsevierStyleHsp" style=""></span>mL) and B (100<span class="elsevierStyleHsp" style=""></span>mL).</p><elsevierMultimedia ident="tbl0015"></elsevierMultimedia><p id="par0140" class="elsevierStylePara elsevierViewall">Intravenous (IV) rehydration was given to 11 children, five from the bromopride group and six from the metoclopramide group (<span class="elsevierStyleItalic">p</span><span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>0.658). No patients needed IV rehydration in the ondansetron group (<span class="elsevierStyleItalic">p</span><span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>0.033). Seven children returned to the PedER due to vomiting (<a class="elsevierStyleCrossRef" href="#tbl0015">Table 3</a>).</p></span><span id="sec0075" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0135">Side effects</span><p id="par0145" class="elsevierStylePara elsevierViewall">At 60<span class="elsevierStyleHsp" style=""></span>min post-treatment, the group that showed fewest adverse effects was Group C (24.1%), while groups A and B reported twice as many adverse events; 44.8% and 46.5%, respectively (<span class="elsevierStyleItalic">p</span><span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>0.020). The most common side effect was somnolence in all three groups; however, this was less prevalent in Group C than Groups A and B (<a class="elsevierStyleCrossRef" href="#tbl0015">Table 3</a>). At 24<span class="elsevierStyleHsp" style=""></span>h, Group C showed less side effects than Groups A and B, but this was not statistically significant (<span class="elsevierStyleItalic">p</span><span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>0.752).</p><p id="par0150" class="elsevierStylePara elsevierViewall">There were no statistical differences in diarrhea episodes after using the anti-emetics in any of the medication groups.</p></span></span><span id="sec0080" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0140">Discussion</span><span id="sec0085" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0145">Interpretation</span><p id="par0155" class="elsevierStylePara elsevierViewall">The results showed that bromopride, metoclopramide, and ondansetron are effective anti-emetic medications for treating vomiting in children, with relatively benign safety profiles. Of the three drugs we tested, ondansetron demonstrated to have the best therapeutic profile in terms of effectiveness and amount of oral fluids accepted after the administration of the drug; it was also associated with a lower frequency of side effects.<a class="elsevierStyleCrossRef" href="#bib0160"><span class="elsevierStyleSup">15</span></a></p><p id="par0160" class="elsevierStylePara elsevierViewall">The scientific literature supports the use of anti-emetics for treating persistent vomiting.<a class="elsevierStyleCrossRef" href="#bib0120"><span class="elsevierStyleSup">7</span></a> A study conducted in the USA revealed that most emergency pediatricians prescribe anti-emetics to treat vomiting, considering that it is distressing and unpleasant to children and caregivers.<a class="elsevierStyleCrossRef" href="#bib0150"><span class="elsevierStyleSup">13</span></a> A study conducted in Italy had similar results.<a class="elsevierStyleCrossRef" href="#bib0165"><span class="elsevierStyleSup">16</span></a></p><p id="par0165" class="elsevierStylePara elsevierViewall">Apart from their efficacy, clinicians will often use medications based on their safety profile. Ondansetron has been shown to be effective in preventing vomiting, allowing oral rehydration and limiting IV rehydration use for patients with AGE, while having relatively few side effects.<a class="elsevierStyleCrossRefs" href="#bib0105"><span class="elsevierStyleSup">4,7</span></a> Several studies have compared the effectiveness of ondansetron to placebo, and have shown that ondansetron is more effective in treating vomiting, reducing admission rates; however, some studies report diarrhea with the use of ondansetron, probably due to its prokinetic effect.<a class="elsevierStyleCrossRefs" href="#bib0140"><span class="elsevierStyleSup">11,12,17</span></a></p><p id="par0170" class="elsevierStylePara elsevierViewall">According to different authors, six hours after the administration of anti-emetic medication may be the most suitable time period to assess its effectiveness. There appears to be benefits from using ondansetron in comparison to bromopride and metoclopramide. In the present study, ondansetron was more effective six (<span class="elsevierStyleItalic">p</span><span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>0.023) and 24<span class="elsevierStyleHsp" style=""></span>h (<span class="elsevierStyleItalic">p</span><span class="elsevierStyleHsp" style=""></span>≤<span class="elsevierStyleHsp" style=""></span>0.001) after administration in reducing the incidence of vomiting, compared to the other drugs. It showed a low rate of side effects, was more successful in oral rehydration, prevented IV rehydration, and prevented hospital admission (<span class="elsevierStyleItalic">p</span><span class="elsevierStyleHsp" style=""></span>≤<span class="elsevierStyleHsp" style=""></span>0.05). Bromopride and metoclopramide were considered effective but caused adverse effects, mainly in the first hour after medication, such as somnolence, which may increase the observation time and hospital costs.</p><p id="par0175" class="elsevierStylePara elsevierViewall">Cubeddu et al. compared the therapeutic effectiveness of ondansetron, metoclopramide, and a placebo in control of vomiting, 24<span class="elsevierStyleHsp" style=""></span>h after receiving anti-emetics.<a class="elsevierStyleCrossRef" href="#bib0155"><span class="elsevierStyleSup">14</span></a> Ondansetron was more effective in controlling vomiting compared to metoclopramide and the placebo. The limitation of this study was the small sample size. A study conducted by Al-Ansari et al. evaluated the time to vomiting cessation during episodes of AGE and revealed that both ondansetron and metoclopramide were equally effective in this context.<a class="elsevierStyleCrossRef" href="#bib0130"><span class="elsevierStyleSup">9</span></a> Some authors concerned about side effects from anti-emetics, like diarrhea or dystonic reaction, have described that metoclopramide can cause extrapyramidal symptoms and sedation in children.<a class="elsevierStyleCrossRefs" href="#bib0095"><span class="elsevierStyleSup">2,7,10</span></a></p><p id="par0180" class="elsevierStylePara elsevierViewall">The present study investigated whether the anti-emetic medications studied were associated with the development of diarrhea. Neither drug was shown to cause significant diarrhea in the cohort studied. Al-Ansari et al., also failed to show an association between anti emetic use and diarrhea.<a class="elsevierStyleCrossRef" href="#bib0130"><span class="elsevierStyleSup">9</span></a> Cubeddu et al. had previously suggested that diarrhea may be related to the use of metoclopramide.<a class="elsevierStyleCrossRef" href="#bib0155"><span class="elsevierStyleSup">14</span></a> Although the prokinetic effect of metoclopramide could contribute to this side effect, one would expect ondansetron to cause similar symptoms given its mechanism of action. A study mentions that the increased incidence of diarrhea can be considered as resulting from toxin retention, which could have been eliminated by vomiting.<a class="elsevierStyleCrossRef" href="#bib0115"><span class="elsevierStyleSup">6</span></a></p><p id="par0185" class="elsevierStylePara elsevierViewall">To the authors’ knowledge, this is the only study that has compared the therapeutic effectiveness of bromopride, metoclopramide, and ondansetron in the treatment of acute onset vomiting in a pediatric cohort treated at the emergency department.</p></span><span id="sec0090" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0150">Limitations</span><p id="par0190" class="elsevierStylePara elsevierViewall">The main limitation of the present study is that the clinicians caring for the children in the emergency department, as well as parents and caregivers, were not blinded to the intervention. However, randomization of the medication minimized this potential bias. In addition, there was no placebo arm; however, these children were treated as per routine clinical practice that includes the use of anti-emetic medications. Specific diagnosis was not included in the eligibility criteria; however, vomiting without a definitive diagnosis is a common complaint in pediatric emergency departments, and randomization controlled this potential bias.</p><p id="par0195" class="elsevierStylePara elsevierViewall">In conclusion, it was found that bromopride, metoclopramide, and ondansetron are effective anti-emetic medications for treating vomiting in children, hence preventing dehydration, use of IV fluids, and hospitalization. Ondansetron was superior to the other two agents studied in achieving emesis control and also had fewer side effects.</p></span></span><span id="sec0095" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0155">Registration number: RBR-5ky3ks</span><p id="par0200" class="elsevierStylePara elsevierViewall">Name of trial registry: Randomized clinical trial, comparing the therapeutic effectiveness of intramuscular bromopride, metoclopramide, and ondansetron in the treatment of vomiting.</p><p id="par0205" class="elsevierStylePara elsevierViewall">Protocol: The Brazilian Clinical Trials Registry/clinicaltrials.gov. Identifier: RBR-5ky3ks.</p></span><span id="sec0100" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0160">Funding</span><p id="par0210" class="elsevierStylePara elsevierViewall">The study received funding from HUSM.</p></span><span id="sec0105" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0165">Conflicts of interest</span><p id="par0215" class="elsevierStylePara elsevierViewall">The authors declare no conflicts of interest.</p></span></span>" "textoCompletoSecciones" => array:1 [ "secciones" => array:12 [ 0 => array:3 [ "identificador" => "xres1402837" "titulo" => "Abstract" "secciones" => array:4 [ 0 => array:2 [ "identificador" => "abst0005" "titulo" => "Objective" ] 1 => array:2 [ "identificador" => "abst0010" "titulo" => "Methods" ] 2 => array:2 [ "identificador" => "abst0015" "titulo" => "Results" ] 3 => array:2 [ "identificador" => "abst0020" "titulo" => "Conclusions" ] ] ] 1 => array:2 [ "identificador" => "xpalclavsec1284283" "titulo" => "Keywords" ] 2 => array:3 [ "identificador" => "xres1402836" "titulo" => "Resumo" "secciones" => array:4 [ 0 => array:2 [ "identificador" => "abst0025" "titulo" => "Objetivo" ] 1 => array:2 [ "identificador" => "abst0030" "titulo" => "Métodos" ] 2 => array:2 [ "identificador" => "abst0035" "titulo" => "Resultados" ] 3 => array:2 [ "identificador" => "abst0040" "titulo" => "Conclusões" ] ] ] 3 => array:2 [ "identificador" => "xpalclavsec1284284" "titulo" => "Palavras-chave" ] 4 => array:2 [ "identificador" => "sec0005" "titulo" => "Introduction" ] 5 => array:3 [ "identificador" => "sec0010" "titulo" => "Methods" "secciones" => array:6 [ 0 => array:2 [ "identificador" => "sec0015" "titulo" => "Trial design" ] 1 => array:2 [ "identificador" => "sec0020" "titulo" => "Changes in trial design" ] 2 => array:2 [ "identificador" => "sec0025" "titulo" => "Study setting" ] 3 => array:2 [ "identificador" => "sec0030" "titulo" => "Eligibility criteria for participants" ] 4 => array:2 [ "identificador" => "sec0035" "titulo" => "Interventions" ] 5 => array:2 [ "identificador" => "sec0040" "titulo" => "Outcomes" ] ] ] 6 => array:3 [ "identificador" => "sec0045" "titulo" => "Results" "secciones" => array:6 [ 0 => array:2 [ "identificador" => "sec0050" "titulo" => "Participant flow" ] 1 => array:2 [ "identificador" => "sec0055" "titulo" => "Losses and exclusions" ] 2 => array:2 [ "identificador" => "sec0060" "titulo" => "Baseline data" ] 3 => array:2 [ "identificador" => "sec0065" "titulo" => "Numbers analyzed" ] 4 => array:2 [ "identificador" => "sec0070" "titulo" => "Outcomes" ] 5 => array:2 [ "identificador" => "sec0075" "titulo" => "Side effects" ] ] ] 7 => array:3 [ "identificador" => "sec0080" "titulo" => "Discussion" "secciones" => array:2 [ 0 => array:2 [ "identificador" => "sec0085" "titulo" => "Interpretation" ] 1 => array:2 [ "identificador" => "sec0090" "titulo" => "Limitations" ] ] ] 8 => array:2 [ "identificador" => "sec0095" "titulo" => "Registration number: RBR-5ky3ks" ] 9 => array:2 [ "identificador" => "sec0100" "titulo" => "Funding" ] 10 => array:2 [ "identificador" => "sec0105" "titulo" => "Conflicts of interest" ] 11 => array:1 [ "titulo" => "References" ] ] ] "pdfFichero" => "main.pdf" "tienePdf" => true "fechaRecibido" => "2016-10-31" "fechaAceptado" => "2017-02-15" "PalabrasClave" => array:2 [ "en" => array:1 [ 0 => array:4 [ "clase" => "keyword" "titulo" => "Keywords" "identificador" => "xpalclavsec1284283" "palabras" => array:3 [ 0 => "Clinical trial" 1 => "Antiemetics" 2 => "Vomiting" ] ] ] "pt" => array:1 [ 0 => array:4 [ "clase" => "keyword" "titulo" => "Palavras-chave" "identificador" => "xpalclavsec1284284" "palabras" => array:3 [ 0 => "Ensaio clínico" 1 => "Antieméticos" 2 => "Vômito" ] ] ] ] "tieneResumen" => true "resumen" => array:2 [ "en" => array:3 [ "titulo" => "Abstract" "resumen" => "<span id="abst0005" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0010">Objective</span><p id="spar0005" class="elsevierStyleSimplePara elsevierViewall">To compare the effectiveness of a single intramuscular dose of bromopride, metoclopramide, or ondansetron for treating vomiting.</p></span> <span id="abst0010" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0015">Methods</span><p id="spar0010" class="elsevierStyleSimplePara elsevierViewall">Randomized controlled trial including children 1–12 years of age presenting with acute vomiting at the pediatric emergency department. Outcomes: Number of children that stopped vomiting at one, six, and 24<span class="elsevierStyleHsp" style=""></span>h following treatment; episodes of diarrhea; acceptance of oral liquids; intravenous rehydration; return to hospital and side effects.</p></span> <span id="abst0015" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0020">Results</span><p id="spar0020" class="elsevierStyleSimplePara elsevierViewall">There were 175 children who completed the study. Within the first hour after treatment, all drugs were equally effective, with ondansetron preventing vomiting in 100%, bromopride in 96.6%, and metoclopramide in 94.8% of children (<span class="elsevierStyleItalic">p</span><span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>0.288). Within six hours, ondansetron was successful in preventing vomiting in 98.3% of children, compared to bromopride and metoclopramide, which were successful in 91.5% and 84.4% of patients, respectively (<span class="elsevierStyleItalic">p</span><span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>0.023). Within 24<span class="elsevierStyleHsp" style=""></span>h, ondansetron was superior to both other agents, as it remained efficacious in reducing vomiting in 96.6% of children, as opposed to 67.8% and 67.2% with bromopride and metoclopramide, respectively (<span class="elsevierStyleItalic">p</span><span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>0.001). The ondansetron group showed better acceptance of oral liquids (<span class="elsevierStyleItalic">p</span><span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>0.05) when compared to the bromopride and metoclopramide. The ondansetron group did not show any side effects in 75.9% of cases, compared to 54.2% and 53.5% in the bromopride and metoclopramide groups, respectively. Somnolence was the most common side effect.</p></span> <span id="abst0020" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0025">Conclusions</span><p id="spar0025" class="elsevierStyleSimplePara elsevierViewall">A single dose of ondansetron is superior to bromopride and metoclopramide in preventing vomiting six hours and 24<span class="elsevierStyleHsp" style=""></span>h following treatment. Oral fluid intake after receiving medication was statistically better with Ondansetronwhile also having less side effects compared to the other two agents.</p></span>" "secciones" => array:4 [ 0 => array:2 [ "identificador" => "abst0005" "titulo" => "Objective" ] 1 => array:2 [ "identificador" => "abst0010" "titulo" => "Methods" ] 2 => array:2 [ "identificador" => "abst0015" "titulo" => "Results" ] 3 => array:2 [ "identificador" => "abst0020" "titulo" => "Conclusions" ] ] ] "pt" => array:3 [ "titulo" => "Resumo" "resumen" => "<span id="abst0025" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0035">Objetivo</span><p id="spar0030" class="elsevierStyleSimplePara elsevierViewall">Para comparar a eficácia de uma única dose intramuscular de bromoprida, metoclopramida ou ondansetrona no tratamento de vômito.</p></span> <span id="abst0030" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0040">Métodos</span><p id="spar0035" class="elsevierStyleSimplePara elsevierViewall">Ensaio controlado randomizado incluindo crianças de 1 a 12 anos de idade que apresentam vômito agudo no departamento de emergência pediátrica. Desfechos: Número de crianças que pararam de vomitar 1, 6 e 24 horas após o tratamento; episódios de diarreia; aceitação de líquidos orais; reidratação intravenosa, retorno ao hospital e efeitos colaterais.</p></span> <span id="abst0035" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0045">Resultados</span><p id="spar0045" class="elsevierStyleSimplePara elsevierViewall">175 crianças concluíram o estudo. Na primeira hora após o tratamento, todos os medicamentos foram igualmente eficazes, sendo que a ondansetrona preveniu vômito em 100%, a bromoprida em 96,6% e metoclopramida em 94,8% das crianças (p<span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>0,288). Em 6 horas, a ondansetrona mostrou sucesso na prevenção do vômito em 98,3% das crianças, em comparação à bromoprida e à metoclopramida, que mostraram sucesso em 91,5% e 84,4% dos pacientes, respectivamente (p<span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>0,023). Em 24 horas, a ondansetrona foi superior aos dois outros agentes, pois ela continuou eficaz na redução do vômito em 96,6% das crianças, diferente de 67,8% e 67,2% com bromoprida e metoclopramida, respectivamente (p<span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>0,001). O grupo de ondansetrona mostrou melhor aceitação de líquidos orais (p<span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>0,05) em comparação a bromoprida e metoclopramida. O grupo de ondansetrona não mostrou efeitos colaterais em 75,9% dos casos, em comparação a 54,2% e 53,5% dos grupos de bromoprida e metoclopramida. O efeito colateral mais comum foi sonolência.</p></span> <span id="abst0040" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0050">Conclusões</span><p id="spar0050" class="elsevierStyleSimplePara elsevierViewall">Uma única dose de ondansetrona é superior a bromoprida e metoclopramida no tratamento de vômito 6 horas e 24 horas após o tratamento. A ingestão de fluídos orais após receber medicação foi estatisticamente melhor com ondansetrona, ao mesmo tempo em que também apresentando menos efeitos colaterais em comparação aos outros dois agentes.</p></span>" "secciones" => array:4 [ 0 => array:2 [ "identificador" => "abst0025" "titulo" => "Objetivo" ] 1 => array:2 [ "identificador" => "abst0030" "titulo" => "Métodos" ] 2 => array:2 [ "identificador" => "abst0035" "titulo" => "Resultados" ] 3 => array:2 [ "identificador" => "abst0040" "titulo" => "Conclusões" ] ] ] ] "NotaPie" => array:1 [ 0 => array:2 [ "etiqueta" => "☆" "nota" => "<p class="elsevierStyleNotepara" id="npar0055">Please cite this article as: Epifanio M, Portela JL, Piva JP, Ferreira CH, Icaza EE, Mattiello R. Bromopride, metoclopramide, or ondansetron for the treatment of vomiting in the pediatric emergency department: a randomized controlled trial. J Pediatr (Rio J). 2018;94:62–8.</p>" ] ] "multimedia" => array:4 [ 0 => array:7 [ "identificador" => "fig0005" "etiqueta" => "Figure 1" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr1.jpeg" "Alto" => 2050 "Ancho" => 2236 "Tamanyo" => 235285 ] ] "descripcion" => array:1 [ "en" => "<p id="spar0055" class="elsevierStyleSimplePara elsevierViewall">CONSORT flowchart of enrollment, treatment, and follow-up.</p>" ] ] 1 => array:8 [ "identificador" => "tbl0005" "etiqueta" => "Table 1" "tipo" => "MULTIMEDIATABLA" "mostrarFloat" => true "mostrarDisplay" => false "detalles" => array:1 [ 0 => array:3 [ "identificador" => "at1" "detalle" => "Table " "rol" => "short" ] ] "tabla" => array:3 [ "leyenda" => "<p id="spar0065" class="elsevierStyleSimplePara elsevierViewall">IQR, interquartile range; <span class="elsevierStyleItalic">n</span>, number of patients.</p>" "tablatextoimagen" => array:1 [ 0 => array:2 [ "tabla" => array:1 [ 0 => """ <table border="0" frame="\n \t\t\t\t\tvoid\n \t\t\t\t" class=""><thead title="thead"><tr title="table-row"><th class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="" valign="\n \t\t\t\t\ttop\n \t\t\t\t" scope="col" style="border-bottom: 2px solid black"> \t\t\t\t\t\t\n \t\t\t\t\t\t</th><th class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " colspan="2" align="center" valign="\n \t\t\t\t\ttop\n \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Total</th><th class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Bromopride (<span class="elsevierStyleItalic">n</span><span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>59) \t\t\t\t\t\t\n \t\t\t\t\t\t</th><th class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Metoclopramide (<span class="elsevierStyleItalic">n</span><span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>58) \t\t\t\t\t\t\n \t\t\t\t\t\t</th><th class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Ondansetron (<span class="elsevierStyleItalic">n</span><span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>58) \t\t\t\t\t\t\n \t\t\t\t\t\t</th><th class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t" scope="col" style="border-bottom: 2px solid black"><span class="elsevierStyleItalic">p</span> \t\t\t\t\t\t\n \t\t\t\t\t\t</th></tr></thead><tbody title="tbody"><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Gender (male) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"><span class="elsevierStyleItalic">n</span> (%) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">90 (51.4) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">26 (44.1) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">34 (58.6) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">30 (51.7) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">0.289<a class="elsevierStyleCrossRef" href="#tblfn0005"><span class="elsevierStyleSup">a</span></a> \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Age (years) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Median (IQR) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">3.0 (1.0–6.0) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">3.0 (1.0–6) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">2.0 (1.0–4.0) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">3.5 (2.0–7.3) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">0.091<a class="elsevierStyleCrossRef" href="#tblfn0010"><span class="elsevierStyleSup">b</span></a> \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Weight (kg) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Median (IQR) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">14.0 (11.2–23.7) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">13.6 (11.0–26.5) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">13.1 (10.9–18.8) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">16.0 (13.0–25.7) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">0.243<a class="elsevierStyleCrossRef" href="#tblfn0010"><span class="elsevierStyleSup">b</span></a> \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Vomits (24<span class="elsevierStyleHsp" style=""></span>h) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Median (IQR) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">5.0 (3.0–7.0) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">4.5 (3.0–7.0) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">5.0 (3.0–8.0) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">5.0 (3.0–7.0) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">0.505<a class="elsevierStyleCrossRef" href="#tblfn0010"><span class="elsevierStyleSup">b</span></a> \t\t\t\t\t\t\n \t\t\t\t</td></tr></tbody></table> """ ] "imagenFichero" => array:1 [ 0 => "xTab2405940.png" ] ] ] "notaPie" => array:2 [ 0 => array:3 [ "identificador" => "tblfn0005" "etiqueta" => "a" "nota" => "<p class="elsevierStyleNotepara" id="npar0005">Pearson's chi-squared test.</p>" ] 1 => array:3 [ "identificador" => "tblfn0010" "etiqueta" => "b" "nota" => "<p class="elsevierStyleNotepara" id="npar0010">Kruskal–Wallis test:</p>" ] ] ] "descripcion" => array:1 [ "en" => "<p id="spar0060" class="elsevierStyleSimplePara elsevierViewall">Baseline characteristics of children treated for vomiting with bromopride, metoclopramide, and ondansetron intramuscular.</p>" ] ] 2 => array:8 [ "identificador" => "tbl0010" "etiqueta" => "Table 2" "tipo" => "MULTIMEDIATABLA" "mostrarFloat" => true "mostrarDisplay" => false "detalles" => array:1 [ 0 => array:3 [ "identificador" => "at2" "detalle" => "Table " "rol" => "short" ] ] "tabla" => array:2 [ "tablatextoimagen" => array:1 [ 0 => array:2 [ "tabla" => array:1 [ 0 => """ <table border="0" frame="\n \t\t\t\t\tvoid\n \t\t\t\t" class=""><thead title="thead"><tr title="table-row"><th class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="" valign="\n \t\t\t\t\ttop\n \t\t\t\t" scope="col" style="border-bottom: 2px solid black"> \t\t\t\t\t\t\n \t\t\t\t\t\t</th><th class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Bromopride (<span class="elsevierStyleItalic">n</span><span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>59) \t\t\t\t\t\t\n \t\t\t\t\t\t</th><th class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Metoclopramide (<span class="elsevierStyleItalic">n</span><span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>58) \t\t\t\t\t\t\n \t\t\t\t\t\t</th><th class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Ondansetron (<span class="elsevierStyleItalic">n</span><span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>58) \t\t\t\t\t\t\n \t\t\t\t\t\t</th><th class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t" scope="col" style="border-bottom: 2px solid black"><span class="elsevierStyleItalic">p</span> \t\t\t\t\t\t\n \t\t\t\t\t\t</th></tr></thead><tbody title="tbody"><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Vomit (60<span class="elsevierStyleHsp" style=""></span>min), <span class="elsevierStyleItalic">n</span> (%) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">2 (3.4) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">3 (5.2) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">0 (0) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">0.288 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Vomit (6<span class="elsevierStyleHsp" style=""></span>h), <span class="elsevierStyleItalic">n</span> (%) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">5 (8.5) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">9 (15.6) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">1 (1.7) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">0.023<a class="elsevierStyleCrossRefs" href="#tblfn0015"><span class="elsevierStyleSup">a,b</span></a> \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Vomit (24<span class="elsevierStyleHsp" style=""></span>h), <span class="elsevierStyleItalic">n</span> (%) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">19 (32.2) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">19 (32.8) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">2 (3.4) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t"><0.001<a class="elsevierStyleCrossRefs" href="#tblfn0015"><span class="elsevierStyleSup">a,c</span></a> \t\t\t\t\t\t\n \t\t\t\t</td></tr></tbody></table> """ ] "imagenFichero" => array:1 [ 0 => "xTab2405939.png" ] ] ] "notaPie" => array:3 [ 0 => array:3 [ "identificador" => "tblfn0015" "etiqueta" => "a" "nota" => "<p class="elsevierStyleNotepara" id="npar0015">Fisher's exact test.</p>" ] 1 => array:3 [ "identificador" => "tblfn0020" "etiqueta" => "b" "nota" => "<p class="elsevierStyleNotepara" id="npar0020">Metoclopramide <span class="elsevierStyleItalic">vs.</span> bromopride and ondansetron.</p>" ] 2 => array:3 [ "identificador" => "tblfn0025" "etiqueta" => "c" "nota" => "<p class="elsevierStyleNotepara" id="npar0025">Ondansetron <span class="elsevierStyleItalic">vs.</span> metoclopramide and bromopride.</p>" ] ] ] "descripcion" => array:1 [ "en" => "<p id="spar0070" class="elsevierStyleSimplePara elsevierViewall">Comparison between bromopride, metoclopramide and ondansetron groups at 60<span class="elsevierStyleHsp" style=""></span>min, six hours, and 24<span class="elsevierStyleHsp" style=""></span>h after medicating.</p>" ] ] 3 => array:8 [ "identificador" => "tbl0015" "etiqueta" => "Table 3" "tipo" => "MULTIMEDIATABLA" "mostrarFloat" => true "mostrarDisplay" => false "detalles" => array:1 [ 0 => array:3 [ "identificador" => "at3" "detalle" => "Table " "rol" => "short" ] ] "tabla" => array:3 [ "leyenda" => "<p id="spar0080" class="elsevierStyleSimplePara elsevierViewall">IV, intravenous.</p>" "tablatextoimagen" => array:1 [ 0 => array:2 [ "tabla" => array:1 [ 0 => """ <table border="0" frame="\n \t\t\t\t\tvoid\n \t\t\t\t" class=""><thead title="thead"><tr title="table-row"><th class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="" valign="\n \t\t\t\t\ttop\n \t\t\t\t" scope="col" style="border-bottom: 2px solid black"> \t\t\t\t\t\t\n \t\t\t\t\t\t</th><th class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Bromopride (<span class="elsevierStyleItalic">n</span><span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>59) \t\t\t\t\t\t\n \t\t\t\t\t\t</th><th class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Metoclopramide (<span class="elsevierStyleItalic">n</span><span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>58) \t\t\t\t\t\t\n \t\t\t\t\t\t</th><th class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Ondansetron (<span class="elsevierStyleItalic">n</span><span class="elsevierStyleHsp" style=""></span>=<span class="elsevierStyleHsp" style=""></span>58) \t\t\t\t\t\t\n \t\t\t\t\t\t</th><th class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t" scope="col" style="border-bottom: 2px solid black"><span class="elsevierStyleItalic">p</span> \t\t\t\t\t\t\n \t\t\t\t\t\t</th></tr></thead><tbody title="tbody"><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"><span class="elsevierStyleItalic">Amount of liquid (mL) – Median (interquartile range)</span><a class="elsevierStyleCrossRef" href="#tblfn0030"><span class="elsevierStyleSup">a</span></a> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">150.0 (50.0–200.0) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">100.0 (100.0–200.0) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">200 (100.0–200.0) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">0.050<a class="elsevierStyleCrossRefs" href="#tblfn0035"><span class="elsevierStyleSup">b,c</span></a> \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"><span class="elsevierStyleItalic">IV Rehydration, (yes), n (%)</span> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">5 (8.5) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">6 (10.3) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">0 (0.0) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">0.033<a class="elsevierStyleCrossRefs" href="#tblfn0045"><span class="elsevierStyleSup">d,e</span></a> \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"><span class="elsevierStyleItalic">Return to the PedER, (yes), n (%)</span> \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">3 (5.1) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">3 (5.4) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">1 (1.7) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">0.637<a class="elsevierStyleCrossRef" href="#tblfn0045"><span class="elsevierStyleSup">d</span></a> \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " colspan="5" align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"><span class="elsevierStyleVsp" style="height:0.5px"></span></td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " colspan="5" align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"><span class="elsevierStyleItalic">Side effects (60</span><span class="elsevierStyleHsp" style=""></span><span class="elsevierStyleItalic">min)</span></td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>None \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">32 (54.2) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">31 (53.5) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">44 (75.9) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">0.020<a class="elsevierStyleCrossRefs" href="#tblfn0045"><span class="elsevierStyleSup">d,e</span></a> \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>Somnolence, (yes), <span class="elsevierStyleItalic">n</span> (%) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">26 (44.1) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">26 (44.8) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">12 (20.7) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">0.034<a class="elsevierStyleCrossRefs" href="#tblfn0045"><span class="elsevierStyleSup">d,e</span></a> \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>Diarrhea, (yes), <span class="elsevierStyleItalic">n</span> (%) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">0 (0.0) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">0 (0.0) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">1 (1.7) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="\n \t\t\t\t\ttop\n \t\t\t\t"> \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>Other, (yes), <span class="elsevierStyleItalic">n</span> (%) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">1 (1.7) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">1 (1.7) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">1 (1.7) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="\n \t\t\t\t\ttop\n \t\t\t\t"> \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " colspan="5" align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"><span class="elsevierStyleVsp" style="height:0.5px"></span></td></tr><tr title="table-row"><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " colspan="5" align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"><span class="elsevierStyleItalic">Side effects (24</span><span class="elsevierStyleHsp" style=""></span><span class="elsevierStyleItalic">h)</span></td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>None \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">38 (64.4) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">35 (63.6) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">40 (69.0) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">0.752<a class="elsevierStyleCrossRef" href="#tblfn0045"><span class="elsevierStyleSup">d</span></a> \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>Somnolence,(yes), <span class="elsevierStyleItalic">n</span> (%) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">10 (16.9) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">11 (20.0) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">7 (12.1) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="\n \t\t\t\t\ttop\n \t\t\t\t"> \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>Diarrhea, (yes), <span class="elsevierStyleItalic">n</span> (%) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">3 (5.1) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">5 (9.1) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">3 (5.1) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="\n \t\t\t\t\ttop\n \t\t\t\t"> \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t"><span class="elsevierStyleHsp" style=""></span>Other, (yes), <span class="elsevierStyleItalic">n</span> (%) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">8 (13.6) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">4 (7.3) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="char" valign="\n \t\t\t\t\ttop\n \t\t\t\t">8 (13.8) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="" valign="\n \t\t\t\t\ttop\n \t\t\t\t"> \t\t\t\t\t\t\n \t\t\t\t</td></tr></tbody></table> """ ] "imagenFichero" => array:1 [ 0 => "xTab2405938.png" ] ] ] "notaPie" => array:5 [ 0 => array:3 [ "identificador" => "tblfn0030" "etiqueta" => "a" "nota" => "<p class="elsevierStyleNotepara" id="npar0030">The amount of fluid taken orally was measured one hour after initiating its administration.</p>" ] 1 => array:3 [ "identificador" => "tblfn0035" "etiqueta" => "b" "nota" => "<p class="elsevierStyleNotepara" id="npar0035">Kruskal–Wallis test; pairwise comparison of groups (Dunn <span class="elsevierStyleItalic">post hoc</span> tests).</p>" ] 2 => array:3 [ "identificador" => "tblfn0040" "etiqueta" => "c" "nota" => "<p class="elsevierStyleNotepara" id="npar0040">Ondansetron <span class="elsevierStyleItalic">vs.</span> metoclopramide.</p>" ] 3 => array:3 [ "identificador" => "tblfn0045" "etiqueta" => "d" "nota" => "<p class="elsevierStyleNotepara" id="npar0045">Fisher's exact test; no significant differences.</p>" ] 4 => array:3 [ "identificador" => "tblfn0050" "etiqueta" => "e" "nota" => "<p class="elsevierStyleNotepara" id="npar0050">Ondansetron <span class="elsevierStyleItalic">vs.</span> metoclopramide and bromopride.</p>" ] ] ] "descripcion" => array:1 [ "en" => "<p id="spar0075" class="elsevierStyleSimplePara elsevierViewall">Secondary outcome measures comparing different medications.</p>" ] ] ] "bibliografia" => array:2 [ "titulo" => "References" "seccion" => array:1 [ 0 => array:2 [ "identificador" => "bibs0015" "bibliografiaReferencia" => array:17 [ 0 => array:3 [ "identificador" => "bib0090" "etiqueta" => "1" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Acute diarrhea in adults and children: a global perspective" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:2 [ 0 => "M. Farthing" 1 => "M. Salam" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:5 [ "tituloSerie" => "World Gastroenterol Organ" "fecha" => "2012" "volumen" => "47" "paginaInicial" => "1" "paginaFinal" => "24" ] ] ] ] ] ] 1 => array:3 [ "identificador" => "bib0095" "etiqueta" => "2" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "European Society for Pediatric Gastroenterology, Hepatology, and Nutrition/European Society for Pediatric Infectious Diseases evidence-based guidelines for the management of acute gastroenteritis in children in Europe: update 2014" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:6 [ 0 => "A. Guarino" 1 => "S. Ashkenazi" 2 => "D. Gendrel" 3 => "A. Lo Vecchio" 4 => "R. Shamir" 5 => "H. Szajewska" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1097/MPG.0000000000000375" "Revista" => array:6 [ "tituloSerie" => "JPGN" "fecha" => "2014" "volumen" => "59" "paginaInicial" => "132" "paginaFinal" => "152" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/24739189" "web" => "Medline" ] ] ] ] ] ] ] ] 2 => array:3 [ "identificador" => "bib0100" "etiqueta" => "3" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Oral ondansetron <span class="elsevierStyleItalic">versus</span> domperidone for symptomatic treatment of vomiting during acute gastroenteritis in children: multicentre randomized controlled trial" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "F. Marchetti" 1 => "A. Maestro" 2 => "F. Rovere" 3 => "D. Zanon" 4 => "A. Arrighini" 5 => "P. Bertolani" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1186/1471-2431-11-15" "Revista" => array:6 [ "tituloSerie" => "BMC Pediatr" "fecha" => "2011" "volumen" => "11" "paginaInicial" => "15" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/21310051" "web" => "Medline" ] ] "itemHostRev" => array:3 [ "pii" => "S1521694200900913" "estado" => "S300" "issn" => "15216942" ] ] ] ] ] ] ] 3 => array:3 [ "identificador" => "bib0105" "etiqueta" => "4" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Systematic review with meta-analysis: ondansetron for vomiting in children with acute gastroenteritis" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:4 [ 0 => "E. Tomasik" 1 => "E. Ziółkowska" 2 => "M. Kołodziej" 3 => "H. Szajewska" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1111/apt.13728" "Revista" => array:6 [ "tituloSerie" => "Aliment Pharmacol Ther" "fecha" => "2016" "volumen" => "44" "paginaInicial" => "438" "paginaFinal" => "446" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/27401959" "web" => "Medline" ] ] ] ] ] ] ] ] 4 => array:3 [ "identificador" => "bib0110" "etiqueta" => "5" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Manejo de la gastroenteritis aguda en menores de 5 años: un enfoque basado en la evidencia" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:3 [ 0 => "P. Gutiérrez Castrellón" 1 => "I. Polanco Allué" 2 => "E. Salazar Lindo" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:5 [ "tituloSerie" => "An Pediatría" "fecha" => "2010" "volumen" => "72" "paginaInicial" => "220.e1" "paginaFinal" => "220.e20" ] ] ] ] ] ] 5 => array:3 [ "identificador" => "bib0115" "etiqueta" => "6" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Antiemetics for reducing vomiting related to acute gastroenteritis in children and adolescents" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:3 [ 0 => "Z. Fedorowicz" 1 => "V.A. Jagannath" 2 => "B. Carter" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:4 [ "tituloSerie" => "Cochrane Database Syst Rev" "fecha" => "2011" "volumen" => "9" "paginaInicial" => "CD005506" ] ] ] ] ] ] 6 => array:3 [ "identificador" => "bib0120" "etiqueta" => "7" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Antiemetic treatment for acute gastroenteritis in children: an updated Cochrane systematic review with meta-analysis and mixed treatment comparison in a Bayesian framework" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:2 [ 0 => "B. Carter" 1 => "Z. Fedorowicz" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:4 [ "tituloSerie" => "BMJ Open" "fecha" => "2012" "volumen" => "2" "paginaInicial" => "e000622" ] ] ] ] ] ] 7 => array:3 [ "identificador" => "bib0125" "etiqueta" => "8" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Novas drogas no tratamento da dispepsia funcional" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:1 [ 0 => "LE de A Troncon" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1590/s0004-28032001000300012" "Revista" => array:6 [ "tituloSerie" => "Arq Gastroenterol" "fecha" => "2001" "volumen" => "38" "paginaInicial" => "207" "paginaFinal" => "212" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/11917722" "web" => "Medline" ] ] ] ] ] ] ] ] 8 => array:3 [ "identificador" => "bib0130" "etiqueta" => "9" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Metoclopramide <span class="elsevierStyleItalic">versus</span> ondansetron for the treatment of vomiting in children with acute gastroenteritis" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:5 [ 0 => "K. Al-Ansari" 1 => "S. Alomary" 2 => "H. Abdulateef" 3 => "M. Alshawagfa" 4 => "K. Kamal" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1097/MPG.0b013e3182132d8d" "Revista" => array:6 [ "tituloSerie" => "J Pediatr Gastroenterol Nutr" "fecha" => "2011" "volumen" => "53" "paginaInicial" => "156" "paginaFinal" => "160" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/21788756" "web" => "Medline" ] ] ] ] ] ] ] ] 9 => array:3 [ "identificador" => "bib0135" "etiqueta" => "10" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Acute dystonic reaction to metoclopramide in patients carrying homozygous cytochrome P450 2D6 genetic polymorphisms" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:3 [ 0 => "A. van der Padt" 1 => "R.H.N. van Schaik" 2 => "P. Sonneveld" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "Neth J Med" "fecha" => "2006" "volumen" => "64" "paginaInicial" => "160" "paginaFinal" => "162" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/16702617" "web" => "Medline" ] ] ] ] ] ] ] ] 10 => array:3 [ "identificador" => "bib0140" "etiqueta" => "11" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Ondansetron use in the pediatric emergency room for diagnoses other than acute gastroenteritis" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:4 [ 0 => "J.J. Sturm" 1 => "A. Pierzchala" 2 => "H.K. Simon" 3 => "D.A. Hirsh" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1097/PEC.0b013e3182494d87" "Revista" => array:6 [ "tituloSerie" => "Pediatr Emerg Care" "fecha" => "2012" "volumen" => "28" "paginaInicial" => "247" "paginaFinal" => "250" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/22344213" "web" => "Medline" ] ] ] ] ] ] ] ] 11 => array:3 [ "identificador" => "bib0145" "etiqueta" => "12" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Clinical trial: oral ondansetron for reducing vomiting secondary to acute gastroenteritis in children – a double-blind randomized study" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:3 [ 0 => "H.L. Yilmaz" 1 => "R.D. Yildizdas" 2 => "Y. Sertdemir" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "Aliment Pharmacol Ther" "fecha" => "2010" "volumen" => "31" "paginaInicial" => "82" "paginaFinal" => "91" "itemHostRev" => array:3 [ "pii" => "S0140673617318251" "estado" => "S300" "issn" => "01406736" ] ] ] ] ] ] ] 12 => array:3 [ "identificador" => "bib0150" "etiqueta" => "13" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Antiemetic use in pediatric gastroenteritis: a national survey of emergency physicians, pediatricians, and pediatric emergency physicians" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:3 [ 0 => "K.T. Kwon" 1 => "S.E. Rudkin" 2 => "M.I. Langdorf" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:5 [ "tituloSerie" => "Clin Pediatr (Phila)" "fecha" => "2002" "volumen" => "41" "paginaInicial" => "641" "paginaFinal" => "652" ] ] ] ] ] ] 13 => array:3 [ "identificador" => "bib0155" "etiqueta" => "14" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Antiemetic activity of ondansetron in acute gastroenteritis" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "L.X. Cubeddu" 1 => "L.M. Trujillo" 2 => "I. Talmaciu" 3 => "V. Gonzalez" 4 => "J. Guariguata" 5 => "J. Seijas" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1046/j.1365-2036.1997.97269000.x" "Revista" => array:6 [ "tituloSerie" => "Aliment Pharmacol Ther" "fecha" => "1997" "volumen" => "11" "paginaInicial" => "185" "paginaFinal" => "191" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/9042992" "web" => "Medline" ] ] ] ] ] ] ] ] 14 => array:3 [ "identificador" => "bib0160" "etiqueta" => "15" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Acute diarrhea: evidence-based management" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:3 [ 0 => "K.G. Brandt" 1 => "M.M. Castro Antunes" 2 => "G.A. Silva" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:5 [ "tituloSerie" => "J Pediatr (Rio J)" "fecha" => "2015" "volumen" => "91" "paginaInicial" => "S36" "paginaFinal" => "S43" ] ] ] ] ] ] 15 => array:3 [ "identificador" => "bib0165" "etiqueta" => "16" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Antiemetics for children with gastroenteritis: off-label but still on in clinical practice" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:4 [ 0 => "F. Albano" 1 => "E. Bruzzese" 2 => "M.I. Spagnuolo" 3 => "G. De Marco" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1097/01.mpg.0000232571.56397.0d" "Revista" => array:6 [ "tituloSerie" => "J Pediatr Gastroenterol Nutr" "fecha" => "2006" "volumen" => "43" "paginaInicial" => "402" "paginaFinal" => "404" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/16954969" "web" => "Medline" ] ] ] ] ] ] ] ] 16 => array:3 [ "identificador" => "bib0170" "etiqueta" => "17" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Emergency department use of oral ondansetron for acute gastroenteritis-related vomiting in infants and children" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:1 [ 0 => "A. Cheng" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1093/pch/16.3.177" "Revista" => array:6 [ "tituloSerie" => "Paediatr Child Health" "fecha" => "2011" "volumen" => "16" "paginaInicial" => "177" "paginaFinal" => "182" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/22379383" "web" => "Medline" ] ] ] ] ] ] ] ] ] ] ] ] ] "idiomaDefecto" => "en" "url" => "/00217557/0000009400000001/v2_202010230715/S0021755716302431/v2_202010230715/en/main.assets" "Apartado" => array:4 [ "identificador" => "10179" "tipo" => "SECCION" "en" => array:2 [ "titulo" => "Original articles" "idiomaDefecto" => true ] "idiomaDefecto" => "en" ] "PDF" => "https://static.elsevier.es/multimedia/00217557/0000009400000001/v2_202010230715/S0021755716302431/v2_202010230715/en/main.pdf?idApp=UINPBA000049&text.app=https://jped.elsevier.es/" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0021755716302431?idApp=UINPBA000049" ]
Year/Month | Html | Total | |
---|---|---|---|
2024 November | 9 | 5 | 14 |
2024 October | 48 | 26 | 74 |
2024 September | 77 | 37 | 114 |
2024 August | 58 | 36 | 94 |
2024 July | 68 | 46 | 114 |
2024 June | 39 | 21 | 60 |
2024 May | 37 | 13 | 50 |
2024 April | 43 | 26 | 69 |
2024 March | 62 | 23 | 85 |
2024 February | 63 | 28 | 91 |
2024 January | 167 | 28 | 195 |
2023 December | 32 | 28 | 60 |
2023 November | 43 | 40 | 83 |
2023 October | 50 | 58 | 108 |
2023 September | 45 | 38 | 83 |
2023 August | 39 | 23 | 62 |
2023 July | 28 | 17 | 45 |
2023 June | 27 | 12 | 39 |
2023 May | 44 | 22 | 66 |
2023 April | 36 | 17 | 53 |
2023 March | 53 | 31 | 84 |
2023 February | 33 | 16 | 49 |
2023 January | 21 | 20 | 41 |
2022 December | 60 | 34 | 94 |
2022 November | 35 | 32 | 67 |
2022 October | 64 | 38 | 102 |
2022 September | 28 | 55 | 83 |
2022 August | 38 | 38 | 76 |
2022 July | 43 | 37 | 80 |
2022 June | 35 | 32 | 67 |
2022 May | 30 | 37 | 67 |
2022 April | 41 | 37 | 78 |
2022 March | 32 | 36 | 68 |
2022 February | 33 | 19 | 52 |
2022 January | 21 | 21 | 42 |
2021 December | 16 | 28 | 44 |
2021 November | 14 | 16 | 30 |
2021 October | 10 | 22 | 32 |
2021 September | 10 | 17 | 27 |
2021 August | 11 | 10 | 21 |
2021 July | 8 | 9 | 17 |
2021 June | 8 | 10 | 18 |
2021 May | 14 | 19 | 33 |
2021 April | 48 | 13 | 61 |
2021 March | 24 | 9 | 33 |
2021 February | 34 | 6 | 40 |
2021 January | 26 | 15 | 41 |
2020 December | 18 | 6 | 24 |
2020 November | 23 | 14 | 37 |
2020 October | 16 | 11 | 27 |
2020 September | 31 | 14 | 45 |
2020 August | 13 | 4 | 17 |
2020 July | 11 | 6 | 17 |
2020 June | 14 | 4 | 18 |
2020 May | 27 | 4 | 31 |
2020 April | 24 | 9 | 33 |
2020 March | 19 | 3 | 22 |
2020 February | 26 | 13 | 39 |
2020 January | 20 | 14 | 34 |
2019 December | 14 | 10 | 24 |
2019 November | 10 | 7 | 17 |
2019 October | 9 | 11 | 20 |
2019 September | 10 | 7 | 17 |
2019 August | 8 | 10 | 18 |
2019 July | 16 | 8 | 24 |
2019 June | 12 | 7 | 19 |
2019 May | 17 | 12 | 29 |
2019 April | 25 | 6 | 31 |
2019 March | 16 | 10 | 26 |
2019 February | 10 | 10 | 20 |
2019 January | 12 | 10 | 22 |
2018 December | 8 | 10 | 18 |
2018 November | 36 | 3 | 39 |
2018 October | 255 | 22 | 277 |
2018 September | 115 | 13 | 128 |
2018 August | 31 | 9 | 40 |
2018 July | 52 | 6 | 58 |
2018 June | 48 | 6 | 54 |
2018 May | 102 | 12 | 114 |
2018 April | 14 | 4 | 18 |
2018 March | 51 | 15 | 66 |
2018 February | 48 | 16 | 64 |
2018 January | 25 | 15 | 40 |
2017 December | 2 | 2 | 4 |
2017 November | 1 | 4 | 5 |
2017 October | 2 | 7 | 9 |
2017 September | 0 | 6 | 6 |
2017 August | 0 | 8 | 8 |